- No public price. Homepage advertises "Free for 60 days" trial; the trial page gives no length or terms.
- Attested
- Type II
- 2
- —
- US
Drug info
PrecisePK
by PrecisePK · US
Bayesian model-informed precision dosing software that calculates individualized drug regimens from serum levels, including vancomycin.
On this page
55/100
Editorial rating 4.0 / 5
- Clinical Integration2.9/6.6
epic + oracle (2 of 3 top EHRs)
- Evidence Strength24/27
5 peer-reviewed papers
- Vendor & Market3.9/21.6
Seed-stage or unfunded
- Sentiment & Transparency3/6
Pricing on request, no public amounts
▸ Show all 11 dimensions▾ Hide dimension detail
- EHR integrations (count)1/4
2 EHR integrations
- Top-3 EHR coverage (Epic / Oracle / Athena)2/2
epic + oracle (2 of 3 top EHRs)
- Peer-reviewed papers21/21
5 peer-reviewed papers
- RCT / meta-analysis / systematic review3/6
1 observational study (no RCT)
- Funding & adoption signal4/16
Seed-stage or unfunded
- Years in market0/6
Founded year not recorded
- Pricing transparency3/6
Pricing on request, no public amounts
Bayesian model-informed precision dosing software that calculates individualized drug regimens from serum levels, including vancomycin.
No public price. Homepage advertises "Free for 60 days" trial; the trial page gives no length or terms. HIPAA + SOC 2 Type II attested. integrates with Epic, Cerner.
Evidence record
5 studies on PubMed: 4 other, 1 observational, published 2025 to 2026. Read the literature summary
- Score computed November 2, 2026, method 1.2.0
- Review written November 2, 2026
MedAI Verdict, PrecisePK record, https://medaiverdict.com/tools/precisepk, version November 2, 2026
Bottom line
PrecisePK is Bayesian therapeutic drug monitoring software for model-informed precision dosing, which the company page traces to a program called T.D.M.S. 2000 developed in 1986. The vendor says it individualizes a dose from a single blood-level draw, with vancomycin AUC24 and busulfan AUC targeting among the named uses. Hospital pharmacists and clinicians are the audience, and the homepage advertises a 60-day free trial. A buyer who needs a stated corporate owner or a price list before a pilot gets neither from the vendor.
What do independent papers say about PrecisePK?
In an Oman cohort of 90 inpatients (J Pharmacokinet Pharmacodyn, 2026, PMID 42800832), the PrecisePK Rodvold posterior model had a relative bias of 0.47% and a relative RMSE of 13.18%, which the authors treat as clinically acceptable. The Goti model in DoseMeRx had a bias of 20.17%, and the authors call the Rodvold posterior more suitable.
Fourteen papers name PrecisePK, from 2020 to 2026. None shows a PrecisePK author affiliation, and none is a randomized trial. The vendor cites Turner and colleagues (Pharmacotherapy, 2018, PMID 30362592) as independent validation. That paper reviewed and validated Bayesian dose-optimizing software and equations for calculating the vancomycin AUC in critically ill patients.
What does the vendor say it does?
The homepage lists interactive serum-level graphs, comparison of an individual's results with population models, automatic model adjustment as more patient data arrives, EHR integration and an interface in English, Spanish, Chinese, Thai and Korean. Vancomycin dosing is AUC24-based and described as "fully compliant with 2020 ASHP/IDSA Vancomycin Guidelines". A customer testimonial mentions neonatal, pediatric and adult models and adjustments for obese, critically ill and post-cardiac-surgery patients. A separate AKI Prediction Tool is described as real-time monitoring and analytics for vancomycin AKI risk.
A blog teaser names Epic and Cerner (Oracle Health) as EHR connections. The vendor lists SOC 2 (type not given), ISO/IEC 27001:2013, HIPAA and GDPR, names no HITRUST certification and makes no FDA statement.
The homepage cites outcome figures it attributes to third-party studies: length of stay reduced by up to 10 days, nephrotoxicity reduced by 10.5% and about $60,305 saved per 500 beds per year. It also says GlobalRPH independently endorsed PrecisePK as the Vancomycin AUC Dosing Calculator of choice.
A 1986 program with an unclear owner
The company page says T.D.M.S. 2000 was developed in 1986 by Philip Anderson, PharmD, with consultants, and programmed by Anjum Gupta, PhD, both UC San Diego professors. It was beta-tested in 1987 at UCSD Medical Center and Rady Children's Hospital. The product was rebranded PrecisePK in 2015 as a desktop program, became a web platform in 2019, and added PreciseRx in 2021. Anjum Gupta is the current CEO.
The footer names Healthware, Inc., and the logo tagline reads "A PreciseRX Product". No page explains the link. The headquarters is on Towne Center Drive in San Diego, and founding year, ownership and funding are not stated. Wolters Kluwer is a partner, with PrecisePK integrating into Sentri7. The homepage claims "100+ active partnerships and 10+ countries" and the company page "200+ Trusted Partnerships". The homepage names the U.S. Department of Veterans Affairs and Sharp among its customers.
Free for 60 days, then what?
The homepage advertises "Free for 60 days". The trial page is a sign-up form that states no length, terms or post-trial price, and the site has no pricing page.
The verdict
Hospital pharmacists willing to start on the 60-day trial are the audience, and a buyer who needs a stated corporate owner or a published price first is not.
Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.
What it costs
All tiers are custom-quoted. The vendor does not publish per-provider list pricing.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | Not stated | Not stated | No public price. Homepage advertises "Free for 60 days" trial; the trial page gives no length or terms. |
Source: vendor pricing page. Last checked November 2, 2026.
What deploys cleanly
Carries SOC 2, ISO 27001, HIPAA per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment. Integrates with 2 EHRs: Epic, Cerner.
Who builds it
It was previously known as TDMS, an acquisition or rebrand that healthcare-AI buyers should track when reviewing prior independent coverage.
What the literature says
5 peer-reviewed studies indexed on PubMed evaluate PrecisePK in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.
- Predictive Performance of Bayesian Dosing Software for Vancomycin in Intensive Care Unit Patients. (opens in new tab)
- Bai G, Qi H, Huang Y, et al.· Ther Drug Monit· 2025
- According to the updated guidelines, Bayesian-derived area under the curve estimation is recommended to guide vancomycin dosing. However, the Bayesian dosing software that facilitates this procedure has not been adequately assessed in intensive care unit (ICU) patients. This study evaluated the performance of 3 commonly used Bayesian software programs in predicting vancomycin concentrations in ICU patients before they could be utilized for personalized dosing in this population. Retrospective data from adult ICU patients who were administered vancomycin intravenously were obtained to predict…
- Model-Informed Precision Dosing of Vancomycin in Vietnamese Children: Innovative Midpoint Concentration Monitoring Using 2 Bayesian Programs. (opens in new tab)
- Hai Le B, Phung CK, Yip O, et al.· Ther Drug Monit· 2025
- Bayesian area under the curve (AUC)-guided vancomycin dosing, preferably with 2 samples (2S), is recommended for pediatric patients. However, the timing of sampling may not always be convenient in the clinical setting. In low- to middle-income countries, the implementation of model-informed precision dosing (MIPD) using the Bayesian approach remains limited because of high software costs. Using MIPD with Bayesian analysis, the authors compared the accuracy and precision of midpoint and guideline-recommended 2S strategies and evaluated the clinical utility of an open-source software package an…
- [Free online software tools for precision dosing of vancomycin, and other drugs]. (opens in new tab)
- Quereilhac MI, Taboada GF, Caceres Guido P· Rev Fac Cien Med Univ Nac Cordoba· 2025
- Software tools that assist in the pharmacotherapeutic optimization of narrow therapeutic range drugs are widely available. However, empirical (“trial and error”) methods are still common. The aim of this work was to evaluate the characteristics and performance of free-online software that assist in precision dosing of vancomycin. An exhaustive search was performed in Google, Google Scholar, and Pubmed/Medline, with no time limits. General descriptive and pharmacokinetic characteristics related to vancomycin and, occasionally, to other drugs were evaluated. Different scores were…
- Vancomycin loading dose in a neonatal intensive care unit: experience with therapeutic drug monitoring. (opens in new tab)
- Cabrera Díaz C, González Muñoz C, Izquierdo Copiz G· Andes Pediatr· 2025
- Vancomycin is an antimicrobial widely used in hospitalized newborns (NB), with different dosing schedules that may or may not recommend the use of loading doses, depending on gestational age (GA), weight, and renal function. To evaluate the use of plasma levels after a vancomycin loading dose and its impact on achieving the target area under the curve/minimum inhibitory concentration (AUC/MIC) in a neonatal intensive care unit (NICU). Retrospective, descriptive, and observational study in NBs hospitalized between December 2022 and December 2023, in a high-complexity NICU. All NBs with empiric…
- Evaluation of two model-based Bayesian approaches for vancomycin dosing in general hospitalized patients. (opens in new tab)
- Al-Khirbash AS, Za'abi MA, Al-Maqbali JS, et al.· J Pharmacokinet Pharmacodyn· 2026
- Recent guidelines recommend Bayesian forecasting for vancomycin dosing. However, the agreement and predictive performance of different pharmacokinetic models remain unclear in hospitalized patients in general. This study evaluated two model-based Bayesian approaches implemented in platforms: the Goti et al. model in DoseMeRx and the Rodvold et al. model in PrecisePK. This single-centre prospective cohort study was conducted at Sultan Qaboos University Hospital, Oman, between April and October 2025. Adult inpatients aged ≥ 18 years with normal renal function were incl…
Other drug info
See the full drug info rankingUpToDate Lexidrug
by Wolters Kluwer
Drug reference with interaction analysis, dosing guidance and IV compatibility, from UpToDate (formerly Lexicomp).
No public price, contact form only. Personal subscriptions are also sold (mobile app and store.uptodate.com), but the current personal price is not confirmed.
Epocrates
by Epocrates (athenahealth)
Drug reference app with interaction checks, calculators, disease guidance and a beta AI Assist.
$24.99/mo
Medscape Drug Interaction Checker
by WebMD
Drug interaction lookup for prescription drugs, OTC medications, herbal supplements and some foods, with severity categories.
Free to use per third-party sources (registration may be required). The Medscape page itself states no price.
Drugs.com Professional
by Drugsite Trust
Free drug reference for professionals: AHFS monographs, interaction checker, pill identifier, FDA alerts and shortages. No AI features described.
Free to use with a free sign-up to save drug and interaction lists. Funded by advertising. No Pro subscription or price was found.